CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment

MT Newswires Live2024-12-23

CanSino Biologics (HKG:6185, SHA:688185) said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine ("CS-2036") was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.

The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle (VLP) technology.

The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493378504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493378504","market":"sh","top_or_hot":-1,"title":"CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment","media":"MT Newswires Live","content":"<html><body><p> CanSino Biologics (HKG:6185, SHA:688185) said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine (\"CS-2036\") was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.</p><p>The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle (VLP) technology.</p><p>The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 14:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CanSino Biologics (HKG:6185, SHA:688185) said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine (\"CS-2036\") was officially initiated in Indonesia recently, with the first trial ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493378504","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493378504","pubTimestamp":1734935377,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CanSino Biologics  said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine  was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle  technology.The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688185":"康希诺","BK0239":"医药制造","06185":"康希诺生物","BK1515":"抗疫概念","VLP":"Valero Energy Partners LP","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"康希诺生物脊髓灰质炎疫苗试验获得首例患者登记","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"VLP":1,"06185":0.9},"content_text":"CanSino Biologics (HKG:6185, SHA:688185) said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine (\"CS-2036\") was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle (VLP) technology.The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493378504"}